Repligen

Repligen

RGENPhase 3
Boston, United StatesFounded 1981repligen.com

Repligen is a bioprocessing-focused life sciences company that has been inspiring advances in bioprocessing since 1981. The company develops and commercializes high-value products and flexible solutions that address critical steps in biologic drug production, positioning itself as a technology leader in perfusion, pre-packed columns, and integrated tangential flow filtration systems. With global operations and a focus on process intensification and single-use technologies, Repligen is the fastest-growing bioprocessing tools provider, driven by innovative product development and strategic acquisitions including recent acquisitions of Metenova and FlexBiosys.

Market Cap
$6.4B
Founded
1981

RGEN · Stock Price

USD 113.8866.67 (-36.93%)

Historical price data

AI Company Overview

Repligen is a bioprocessing-focused life sciences company that has been inspiring advances in bioprocessing since 1981. The company develops and commercializes high-value products and flexible solutions that address critical steps in biologic drug production, positioning itself as a technology leader in perfusion, pre-packed columns, and integrated tangential flow filtration systems. With global operations and a focus on process intensification and single-use technologies, Repligen is the fastest-growing bioprocessing tools provider, driven by innovative product development and strategic acquisitions including recent acquisitions of Metenova and FlexBiosys.

Technology Platform

Comprehensive bioprocessing platform including chromatography systems, tangential flow filtration, fluid management solutions, and process analytics for biologic drug manufacturing.

Pipeline Snapshot

10

10 drugs in pipeline, 3 in Phase 3

DrugIndicationStage
RG1068 (Synthetic Human Secretin)AutismPhase 3
RG1068 (synthetic human secretin)PancreatitisPhase 3
RG1068 (Synthetic Human Secretin)AutismPhase 3
RG2417 + PlaceboBipolar I DepressionPhase 2
Subcutaneous SecretinSchizophreniaPhase 2

Opportunities

Strong growth opportunities driven by expanding biologic drug market, new therapeutic modalities like gene therapies and viral vectors, and industry adoption of process intensification technologies.
Recent acquisitions of Metenova and FlexBiosys expand the company's fluid management capabilities and provide vertical integration opportunities.

Risk Factors

Key risks include dependence on biopharmaceutical industry capital expenditure cycles, competitive pressure in bioprocessing tools market, and integration challenges from rapid acquisition strategy.
Supply chain disruptions and regulatory changes affecting biopharmaceutical manufacturing could also impact operations.

Competitive Landscape

Repligen competes as the fastest-growing bioprocessing tools provider, differentiating through first-to-market innovations and comprehensive integrated solutions. The company maintains competitive advantages through technological leadership, global commercial reach, and deep customer relationships built over four decades in the bioprocessing industry.

Publications
20
Patents
20
Pipeline
10

Company Info

TypePlatform
Founded1981
LocationBoston, United States
StagePhase 3
RevenueRevenue Generating

Trading

TickerRGEN
ExchangeNASDAQ

Therapeutic Areas

Bioprocessing TechnologyBiopharmaceutical Manufacturing

Partners

Strategic partners and distributors in select markets
SIMILAR COMPANIES
BASi Research Products
BASi Research Products
Pre-clinical · West Lafayette
Bay BioSciences
Bay BioSciences
Pre-clinical · San Francisco
EydisBio
EydisBio
Pre-clinical · Cambridge
3Spine
3Spine
Pre-clinical · Memphis
Belcher Pharmaceuticals
Belcher Pharmaceuticals
Pre-clinical · Miami
Is this your company?

Claim your profile to update information, add pipeline data, and connect with investors.

Claim profile